Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Multicentre, Randomised, Double-blind, Placebo Controlled, Trial to Evaluate the Safety and Efficacy of Raptiva ® in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Involving Hands and/or Feet, With or Without Pustules.

NCT00739882 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT00739882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00739882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Multicentre, Randomised, Double-blind, Placebo Controlled, Trial to Evaluate the Safety and Efficacy of Raptiva ® in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Involving Hands and/or Feet, With or Without Pustules.
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 4
Overall status
Terminated
Start date
April 30, 2008
Completion date
June 30, 2009
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic plaque psoriasis